b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">29601411</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>24</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>24</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1473-5598</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>36</Volume>\n                    <Issue>7</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>07</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of hypertension</Title>\n                <ISOAbbreviation>J. Hypertens.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1563-1570</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1097/HJH.0000000000001729</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND AND AIM">Treatment-resistant hypertension (TRH) is associated with particular clinical features, nonadherence, and suboptimal treatment. We assessed possible associations of antihypertensive drug classes, specific agents inside each class, and types of combinations, with the presence of non-TRH vs. TRH, and with controlled vs. uncontrolled TRH.</AbstractText>\n                <AbstractText Label="METHODS">Comparisons were done in 14\xe2\x80\x8a264 patients treated with three drugs (non-TRH: 2988; TRH: 11\xe2\x80\x8a276) and in 6974 treated with at least four drugs (controlled TRH: 1383; uncontrolled TRH: 5591). Associations were adjusted for age, sex, and previous cardiovascular event.</AbstractText>\n                <AbstractText Label="RESULTS">In both groups of patients treated with three or with at least four drugs, aldosterone antagonists among drug classes [adjusted odds ratio (OR): 1.82 and 1.41, respectively], and ramipril (OR: 1.28 and 1.30), olmesartan (OR: 1.31 and 1.37), and amlodipine (OR: 1.11 and 1.41) inside each class were significantly associated with blood pressure control (non-TRH or controlled TRH). In patients treated with three drugs, non-TRH was also associated with the use of chlorthalidone (OR: 1.50) and bisoprolol (OR: 1.19), whereas in patients treated with at least four drugs, controlled TRH was significantly associated with the triple combination of a renin-angiotensin system blocker, a calcium channel blocker, and a diuretic (OR: 1.17).</AbstractText>\n                <AbstractText Label="CONCLUSION">The use of aldosterone antagonists is associated with blood pressure control in patients treated with three or more drugs. Similar results are observed with specific agents inside each class, being ramipril, olmesartan, chlorthalidone, amlodipine, and bisoprolol those exhibiting significant results. An increased use of these drugs might probably reduce the burden of TRH.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>de la Sierra</LastName>\n                    <ForeName>Alejandro</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Internal Medicine, Hospital Mutua Terrassa, University of Barcelona.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Armario</LastName>\n                    <ForeName>Pedro</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Internal Medicine, Cardiovascular Risk Area, Hospital Mois\xc3\xa8s Broggi.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Oliveras</LastName>\n                    <ForeName>Anna</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hypertension Unit, Department of Nephrology, Hospital del Mar, Barcelona.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Banegas</LastName>\n                    <ForeName>Jos\xc3\xa9 R</ForeName>\n                    <Initials>JR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Preventive Medicine and Public Health, Universidad Aut\xc3\xb3noma de Madrid, Madrid.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gorostidi</LastName>\n                    <ForeName>Manuel</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Nephrology, Hospital Universitario Central de Asturias, RedinRen, Oviedo.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vinyoles</LastName>\n                    <ForeName>Ernest</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Primary Care Centre La Mina, Barcelona.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>de la Cruz</LastName>\n                    <ForeName>Juan J</ForeName>\n                    <Initials>JJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Preventive Medicine and Public Health, Universidad Aut\xc3\xb3noma de Madrid, Madrid.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Segura</LastName>\n                    <ForeName>Juli\xc3\xa1n</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hypertension Unit, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ruilope</LastName>\n                    <ForeName>Luis M</ForeName>\n                    <Initials>LM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Hypertension Unit, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>J Hypertens</MedlineTA>\n            <NlmUniqueID>8306882</NlmUniqueID>\n            <ISSNLinking>0263-6352</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000451">Mineralocorticoid Receptor Antagonists</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>1J444QC288</RegistryNumber>\n                <NameOfSubstance UI="D017311">Amlodipine</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>8W1IQP3U10</RegistryNumber>\n                <NameOfSubstance UI="C437965">olmesartan</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>L35JN3I7SJ</RegistryNumber>\n                <NameOfSubstance UI="D017257">Ramipril</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>Q0MQD1073Q</RegistryNumber>\n                <NameOfSubstance UI="D002752">Chlorthalidone</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>Y41JS2NL6U</RegistryNumber>\n                <NameOfSubstance UI="D017298">Bisoprolol</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D017311" MajorTopicYN="N">Amlodipine</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017298" MajorTopicYN="N">Bisoprolol</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002752" MajorTopicYN="N">Chlorthalidone</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000451" MajorTopicYN="N">Mineralocorticoid Receptor Antagonists</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>31</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29601411</ArticleId>\n            <ArticleId IdType="doi">10.1097/HJH.0000000000001729</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'